Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Boosted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 21.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,086 shares of the biopharmaceutical company’s stock after buying an additional 2,972 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $3,420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. Oppenheimer & Co. Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.9% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 5,056 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 44 shares during the last quarter. Captrust Financial Advisors lifted its holdings in Alnylam Pharmaceuticals by 4.3% in the 2nd quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock worth $187,000 after purchasing an additional 53 shares during the last quarter. Comerica Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 0.5% during the third quarter. Comerica Bank now owns 11,727 shares of the biopharmaceutical company’s stock worth $2,297,000 after buying an additional 61 shares during the last quarter. Creative Planning lifted its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the third quarter. Creative Planning now owns 2,587 shares of the biopharmaceutical company’s stock worth $518,000 after buying an additional 62 shares during the last quarter. Finally, Ellevest Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 9.9% during the third quarter. Ellevest Inc. now owns 1,088 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 98 shares during the last quarter.

Alnylam Pharmaceuticals Stock Down 1.4 %

Shares of Alnylam Pharmaceuticals stock opened at $199.70 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $117.58 and a 1 year high of $242.97. The business has a 50-day moving average of $221.26 and a two-hundred day moving average of $214.92. The company has a market capitalization of $24.79 billion, a P/E ratio of -21.50 and a beta of 0.49. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.51 and a quick ratio of 3.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last posted its quarterly earnings data on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.45. The business had revenue of $335.04 million during the quarter, compared to the consensus estimate of $312.45 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 109.04%. Alnylam Pharmaceuticals’s quarterly revenue was up 29.6% on a year-over-year basis. During the same period last year, the company earned ($2.16) earnings per share. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.78 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ALNY shares. Citigroup cut their price target on Alnylam Pharmaceuticals from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, February 24th. Canaccord Genuity Group cut their price target on Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating for the company in a report on Friday, February 24th. Piper Sandler boosted their price objective on Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the company an “overweight” rating in a research report on Friday, December 16th. Needham & Company LLC restated a “buy” rating and set a $240.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, February 24th. Finally, Chardan Capital restated a “buy” rating and set a $250.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, February 24th. Seven analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $244.26.

Insider Buying and Selling

In related news, EVP Indrani Lall Franchini sold 1,675 shares of the stock in a transaction dated Thursday, February 2nd. The stock was sold at an average price of $226.01, for a total transaction of $378,566.75. Following the completion of the transaction, the executive vice president now directly owns 3,500 shares in the company, valued at $791,035. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.40% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.